The two main assessment consortia have much in common concerning the types of accommodations and tools for testing special populations, but they part company on some key issues.
Improving minimal residual disease detection: A tumor-informed whole-genome approach. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback